Shortlist

EV/EBIT of 7.7 against a Healthcare median of 22.8 — 66% below peers. Free cash flow yield 12.9%. Trading 70% below its all-time high set 2000-08-25.

At the Healthcare median EV/EBIT of 22.8 instead of its current 7.7, and with earnings unchanged, the equity would be worth about 208% more. That is the size of the gap, not a forecast that it closes.

• ROIC 760% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 48% over three years
• net debt 0.5x EBITDA — balance sheet not forcing anything

Consensus strong buy from 11 analysts, mean target 20.82 USD, 112% above the current price. No revision activity in the last quarter.

Targets spread 96% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Implied upside of 112% is unusually high. The evidence runs the other way here: stocks with the most optimistic targets tend to underperform, because the optimism bias is real and priced-in slowly. Read this as a caution, not an opportunity.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 0.4 against a Technology median of 28.0 — 99% below peers. Free cash flow yield 190.6%. Trading 86% below its all-time high set 2000-03-03.

At the Technology median EV/EBITDA of 18.9 instead of its current 0.3, and with earnings unchanged, the equity would be worth about n/a more. That is the size of the gap, not a forecast that it closes.

• ROIC 33% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 8/9 — accounts improving year on year
• net debt -0.3x EBITDA — balance sheet not forcing anything
• operating margin 17%

mean target 9.67 SEK, 3% below the current price. No revision activity in the last quarter.

Targets spread 35% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Trading 3% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 13.3 against a Consumer Cyclical median of 18.4 — 28% below peers. Free cash flow yield 8.2%. Trading 35% below its all-time high set 2018-09-27.

At the Consumer Cyclical median EV/EBIT of 18.4 instead of its current 13.3, and with earnings unchanged, the equity would be worth about 38% more. That is the size of the gap, not a forecast that it closes.

• ROIC 51% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt 0.0x EBITDA — balance sheet not forcing anything
• Altman Z 10.5 — outside the distress zone

Consensus buy from 12 analysts, mean target 41.50 USD, 14% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 7.2 against a Consumer Defensive median of 16.8 — 57% below peers. Free cash flow yield 13.6%. Trading 49% below its all-time high set 2004-04-21.

At the Consumer Defensive median EV/EBIT of 16.8 instead of its current 7.2, and with earnings unchanged, the equity would be worth about 102% more. That is the size of the gap, not a forecast that it closes.

• ROIC 35% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 7% over three years
• net debt -1.9x EBITDA — balance sheet not forcing anything

mean target 44.00 USD, 31% above the current price. No revision activity in the last quarter.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 4.2 against a Financial Services median of 8.9 — 53% below peers. Free cash flow yield 25.1%. Trading 59% below its all-time high set 2025-06-09.

At the Financial Services median EV/EBIT of 8.9 instead of its current 4.2, and with earnings unchanged, the equity would be worth about 56% more. That is the size of the gap, not a forecast that it closes.

• ROIC 144% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 30% over three years
• net debt -4.0x EBITDA — balance sheet not forcing anything
• Altman Z 13.0 — outside the distress zone

Consensus buy from 14 analysts, mean target 48.43 USD, 56% above the current price. No revision activity in the last quarter.

Targets spread 118% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

P/E of 2.3 against a Communication Services median of 15.3 — 85% below peers.

No usable re-rating gap: the multiple is at or above its sector median, or the inputs were missing.

• ROIC 692% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 5% over three years
• net debt -4.1x EBITDA — balance sheet not forcing anything

Consensus strong buy from 32 analysts, mean target 161.33 CNY, 31% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 19.7 against a Technology median of 28.0 — 30% below peers. Free cash flow yield 6.1%. Trading 55% below its all-time high set 2025-07-30.

At the Technology median EV/EBIT of 28.0 instead of its current 19.7, and with earnings unchanged, the equity would be worth about 43% more. That is the size of the gap, not a forecast that it closes.

• ROIC 19% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 9/9 — accounts improving year on year
• revenue compounding at 14% over three years
• net debt 0.4x EBITDA — balance sheet not forcing anything

Consensus buy from 33 analysts, mean target 446.02 USD, 25% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 150% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 6.2 against a Consumer Defensive median of 16.8 — 63% below peers. Free cash flow yield 6.4%. Trading 39% below its all-time high set 2025-04-23.

At the Consumer Defensive median EV/EBIT of 16.8 instead of its current 6.2, and with earnings unchanged, the equity would be worth about 234% more. That is the size of the gap, not a forecast that it closes.

• ROIC 19% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt 1.3x EBITDA — balance sheet not forcing anything
• Altman Z 3.5 — outside the distress zone

Consensus hold from 7 analysts, mean target 33.64 USD, 6% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 9.4 against a Technology median of 28.0 — 66% below peers. Free cash flow yield 13.6%. Trading 39% below its all-time high set 2026-06-03.

At the Technology median EV/EBIT of 28.0 instead of its current 9.4, and with earnings unchanged, the equity would be worth about 170% more. That is the size of the gap, not a forecast that it closes.

• ROIC 30% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt -1.4x EBITDA — balance sheet not forcing anything
• Altman Z 11.2 — outside the distress zone

mean target 165.00 USD, 52% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 7.8 against a Healthcare median of 22.8 — 66% below peers. Free cash flow yield 6.2%.

At the Healthcare median EV/EBIT of 22.8 instead of its current 7.8, and with earnings unchanged, the equity would be worth about 217% more. That is the size of the gap, not a forecast that it closes.

• ROIC 150% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 35% over three years
• net debt 0.9x EBITDA — balance sheet not forcing anything

Consensus buy from 14 analysts, mean target 99.29 USD, 42% above the current price. Revisions over the last quarter have been net positive, which is the part of analyst output the evidence actually supports.

Targets spread 60% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 6.3 against a Financial Services median of 8.9 — 29% below peers. Free cash flow yield 14.6%.

At the Financial Services median EV/EBIT of 8.9 instead of its current 6.3, and with earnings unchanged, the equity would be worth about 36% more. That is the size of the gap, not a forecast that it closes.

• ROIC 54% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 31% over three years
• operating margin 19%

mean target 150.00 ILS, 22% below the current price. Revisions over the last quarter are balanced.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Trading 22% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 4.9 against a Financial Services median of 8.9 — 46% below peers. Free cash flow yield 24.6%.

At the Financial Services median EV/EBIT of 8.9 instead of its current 4.9, and with earnings unchanged, the equity would be worth about 62% more. That is the size of the gap, not a forecast that it closes.

• ROIC 28% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 26% over three years
• operating margin 27%

Consensus buy from 19 analysts, mean target 111.87 USD, 13% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.